Related Experiment Video
Updated: Feb 12, 2026
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
Published on: April 15, 2022
Novel agents in the frontline management of multiple myeloma
1Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories Hong Kong. h_loong@clo.cuhk.edu.hk
Abstract:
Significant advances in our understanding of the biology of multiple myeloma have led to exciting new opportunities in treatment. The management of this disease is rapidly changing with a plethora of clinical trials initiated with novel agents, namely thalidomide, lenalidomide and bortezomib, either alone or in conjunction with established modalities such as conventional cytotoxic agents and stem-cell transplantation. The combination of these novel agents together with conventional regimens have led to higher response rates and survival, providing options for patients whose disease is otherwise resistant to conventional therapy. These pivotal trials that lead to the approval of these three novel agents in treatment naïve patients. The potential implications in the frontline treatment paradigm of multiple myeloma are discussed.
Insights
Novel agents like thalidomide, lenalidomide, and bortezomib are improving multiple myeloma treatment. Combinations with traditional therapies enhance response rates and survival, offering new options for patients.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Multiple myeloma is a hematologic malignancy with evolving treatment strategies.
- Recent biological insights have spurred the development of novel therapeutic agents.
- Established treatments include cytotoxic agents and stem-cell transplantation.
Purpose of the Study:
- To review the impact of novel agents in multiple myeloma treatment.
- To discuss the implications of new therapies in the frontline setting.
- To highlight advances in managing resistant multiple myeloma.
Main Methods:
- Review of pivotal clinical trials involving thalidomide, lenalidomide, and bortezomib.
- Analysis of combination regimens with conventional therapies.
- Evaluation of treatment outcomes in newly diagnosed patients.
Main Results:
- Novel agents, alone or combined, demonstrate higher response rates.
- Improved survival observed with novel agent-containing regimens.
- Effective options for patients with refractory or relapsed disease.
Conclusions:
- Thalidomide, lenalidomide, and bortezomib represent significant advances in multiple myeloma therapy.
- Combination strategies are redefining the frontline treatment paradigm.
- These agents offer improved outcomes for a broad range of patients.
More Related Videos
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
Related Concept Videos
01:29Subviral Agents
01:49Multiple Allele Traits
01:25Multiple Regression
Farmers can use multiple regression to determine the crop yield based on more than one factor, such as water availability, fertilizer, soil properties, etc. Here, the crop yield is the response or dependent variable as it depends on the other independent variables. The analysis requires the construction of a scatter plot...
01:27Air-entraining Agents
01:26Tonsillitis II: Management
01:25Multiple Voltage Sources
In series, the positive terminal of one battery is connected to the negative terminal of another battery. Hence, the voltage of each battery is added to give the net voltage, which is increased because each battery boosts the electrons that enter it. The same current flows through each battery because they are connected in series.
Batteries are...